The study also assessed the antitumor efficacy of talazoparib in patients with advanced ovarian, breast, or other solid tumors harboring (suspected) deleterious BRCA1/2 mutations, and patients’ tumor biopsies were evaluated for E-cadherin and vimentin, phenotypic biomarkers of epithelial-mesenchymal state, to further understand the potential for carcinomas to adapt to treatment by undergoing epithelial-mesenchymal transition (EMT) and the implications of initial epithelial-mesenchymal phenotype on the response of patients to talazoparib. Here, BRCA1 is linked to neoplasm.